» Articles » PMID: 32017522

Targeted Covalent Inhibition of Telomerase

Overview
Journal ACS Chem Biol
Specialties Biochemistry
Biology
Date 2020 Feb 5
PMID 32017522
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Telomerase is a ribonuceloprotein complex responsible for maintaining telomeres and protecting chromosomal integrity. The human telomerase reverse transcriptase (hTERT) is expressed in ∼90% of cancer cells where it confers the capacity for limitless proliferation. Along with its established role in telomere lengthening, telomerase also serves noncanonical extra-telomeric roles in oncogenic signaling, resistance to apoptosis, and enhanced DNA damage response. We report a new class of natural-product-inspired covalent inhibitors of telomerase that target the catalytic active site.

Citing Articles

Exploiting the Achilles' heel of cancer through a structure-based drug-repurposing approach and experimental validation of top drugs using the TRAP assay.

Kaur D, Chopra M, Saluja D Mol Divers. 2025; .

PMID: 40087255 DOI: 10.1007/s11030-025-11162-1.


Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics.

Shou S, Maolan A, Zhang D, Jiang X, Liu F, Li Y Exp Hematol Oncol. 2025; 14(1):8.

PMID: 39871386 PMC: 11771031. DOI: 10.1186/s40164-025-00597-9.


Prediction of mutation status in gliomas using conventional MRI radiogenomic features.

Tang C, Chen L, Xu Y, Huang L, Zeng Z Front Neurol. 2024; 15:1439598.

PMID: 39131044 PMC: 11310134. DOI: 10.3389/fneur.2024.1439598.


Targeting telomerase reverse transcriptase with the covalent inhibitor NU-1 confers immunogenic radiation sensitization.

Liu Y, Betori R, Pagacz J, Frost G, Efimova E, Wu D Cell Chem Biol. 2022; 29(10):1517-1531.e7.

PMID: 36206753 PMC: 9588800. DOI: 10.1016/j.chembiol.2022.09.002.


Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.

Gao J, Pickett H Nat Rev Cancer. 2022; 22(9):515-532.

PMID: 35790854 DOI: 10.1038/s41568-022-00490-1.


References
1.
Byrd J, Furman R, Coutre S, Flinn I, Burger J, Blum K . Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369(1):32-42. PMC: 3772525. DOI: 10.1056/NEJMoa1215637. View

2.
Crane E, Zabawa T, Farmer R, Scheidt K . Enantioselective synthesis of (-)-exiguolide by iterative stereoselective dioxinone-directed Prins cyclizations. Angew Chem Int Ed Engl. 2011; 50(39):9112-5. PMC: 3273862. DOI: 10.1002/anie.201102790. View

3.
Kim M, Vankayalapati H, Shin-Ya K, Wierzba K, Hurley L . Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. J Am Chem Soc. 2002; 124(10):2098-9. DOI: 10.1021/ja017308q. View

4.
Gondi V, Gravel M, Rawal V . Hydrogen bond catalyzed enantioselective vinylogous Mukaiyama aldol reaction. Org Lett. 2005; 7(25):5657-60. PMC: 2537470. DOI: 10.1021/ol052301p. View

5.
Doksani Y, de Lange T . The role of double-strand break repair pathways at functional and dysfunctional telomeres. Cold Spring Harb Perspect Biol. 2014; 6(12):a016576. PMC: 4292156. DOI: 10.1101/cshperspect.a016576. View